ERBB2 and neoplasm: Breast cancer subtypes with high TILs may also show higher expression of checkpoint molecules such as PD-1 and CTLA-4 (50), which may play a role in higher response rates to checkpoint inhibitors in these tumor subtypes (e.g., ER/PR-HER2-, HER2+) (51).